Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the best dose of T-20, a new anti-HIV drug, to
treat HIV-infected children.
T-20, unlike other anti-HIV medications, lessens the ability of HIV to infect certain cells
(T cells) in the body. Doctors hope to better treat HIV by adding T-20 to anti-HIV drug
combinations that include 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a
nonnucleoside reverse transcriptase inhibitor (NNRTI) and/or a protease inhibitor (PI).
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)